Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of AP23573 in Advanced Sarcoma
2004-002231-92Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Aug 2005
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ridaforolimus in soft tissue sarcoma (STS) and bone cancer, sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Objective response or prolonged stable disease. Started Aug 2005; status: completed.
02
Drugs
ridaforolimus
03
Conditions
soft tissue sarcoma (STS)bone cancer
Beyond the preview
Go deeper on 2004-002231-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002231-92.